The Digital Scalpel: Rewiring European Pathology for an AI-Powered Era

PHILADELPHIA, PA – September 14, 2026 – In a move that signals a tectonic shift in European healthcare, diagnostics giant Unilabs is embarking on a sweeping digital transformation of its pathology services. The company announced it is adopting the AI-powered Concentriq® platform from Philadelphia-based Proscia to unify its vast network, which spans 12 countries and analyzes nine million tissue sections annually. This collaboration is more than a technology upgrade; it represents a foundational rewiring of how cancer and other diseases are diagnosed across the continent, creating a blueprint for the future of precision medicine.

For decades, pathology has been one of the last analog frontiers in medicine. A pathologist’s diagnosis, the gold standard for many diseases, has relied on peering through a microscope at stained tissue on a glass slide. While effective, this process is localized, labor-intensive, and faces mounting pressure from rising caseloads and a shrinking specialist workforce. The Unilabs-Proscia partnership aims to shatter these limitations, moving the entire diagnostic workflow from glass slides to high-resolution digital images accessible on a unified, intelligent platform.

A Blueprint for the Borderless Laboratory

Unilabs operates on a colossal scale, with a network of over 350 pathologists and 400 laboratory technicians. Historically, this expertise has been siloed by geography. A complex case in one country could not easily benefit from the eyes of a sub-specialist in another. The new initiative directly confronts this challenge by creating a single, borderless digital laboratory.

“Behind every test is a person with a story of uncertainty, courage, and hope,” said Badhri Srinivasan, Group CEO of Unilabs. “It is our responsibility to turn that uncertainty into clarity to determine the best course of treatment. Proscia is enabling us to amplify the collective expertise of our network to unlock new levels of care.”

Proscia’s Concentriq platform acts as the central nervous system for this new paradigm. It ingests digital slide images from various scanners and integrates them with laboratory data, creating a comprehensive case file. This allows Unilabs to not only standardize its diagnostic quality but also to dynamically distribute workloads and facilitate seamless remote consultations. A pathologist in Portugal can now provide a second opinion on a case from Sweden in minutes, not days. This centralization of expertise is a powerful response to the growing disparity in access to specialized medical knowledge across Europe.

Under the Hood: The Technology Driving the Change

The technological underpinning for such an ambitious project must be robust, secure, and, crucially, open. The European digital pathology market, projected to grow at a double-digit CAGR and reach hundreds of millions of dollars in the coming years, is rife with solutions. However, many healthcare systems have been hampered by closed, proprietary systems that lead to vendor lock-in and interoperability nightmares.

Proscia’s Concentriq platform was chosen for its enterprise-grade scale and open architecture, which supports over 45 different scanner models and integrates with existing Laboratory Information Systems (LIS). This flexibility is essential for an organization like Unilabs, which operates a diverse ecosystem of laboratory equipment. The platform’s recently unveiled fifth-generation capabilities embed AI directly into the pathologist's workflow, offering intelligent navigation tools, automated quality control checks, and AI-assisted workload balancing.

“Unilabs has long been one of the most trusted diagnostics providers in Europe through decades of clinical and scientific leadership,” said David West, CEO of Proscia. “These same values are now guiding how Unilabs is evolving pathology and advancing precision medicine across its network. With Proscia, it is establishing a blueprint for the future, which laboratories around the world will follow.”

This blueprint is also built on a foundation of rigorous regulatory compliance. The platform is CE-marked under the stringent EU In Vitro Diagnostic Regulation (IVDR), a critical requirement for primary diagnosis, and is designed to adhere to GDPR data privacy rules—a non-negotiable for handling sensitive patient data across national borders.

Accelerating the Promise of Precision Medicine

The ultimate goal of this digital transformation extends far beyond operational efficiency. It aims to accelerate the adoption of precision medicine, where treatments are tailored to the individual genetic and molecular characteristics of a patient's disease. Digital pathology is a cornerstone of this vision.

By digitizing tissue samples, Unilabs creates a massive, data-rich resource. Proscia’s platform allows AI applications to be layered on top of this data to perform tasks that are impossible for the human eye alone. These algorithms can precisely quantify biomarker expression, count mitotic figures, and even identify subtle patterns that may predict a patient’s response to a specific therapy. This is particularly vital for the development and deployment of image-based companion diagnostics (CDx), which match patients to targeted treatments.

The partnership will allow Unilabs’ pathologists to seamlessly access these AI tools, integrating them into routine care. The expected impact is significant, with industry studies suggesting that digital workflows can improve turnaround times by 10% or more. For a cancer patient awaiting a diagnosis, this acceleration is invaluable. Furthermore, by augmenting human expertise with AI-driven insights, the system promises to enhance diagnostic accuracy and reduce the inter-observer variability that can sometimes occur between pathologists.

Navigating Europe's Digital Health Gauntlet

While the Unilabs-Proscia deal represents a major leap forward, it unfolds against a complex backdrop. The adoption of digital pathology in Europe, while accelerating, has been uneven. Northern European nations have been early adopters, spurred by government funding and integrated healthcare networks. Other regions have moved more slowly, hindered by high upfront costs, a lack of clear reimbursement policies, and cultural resistance to change.

Industry experts describe digital pathology as a “game-changer” for workflow and accessibility but acknowledge that the business case can be challenging for smaller institutions. The sheer scale of the Unilabs network, however, allows it to leverage efficiencies that smaller labs cannot, making this large-scale investment viable. The collaboration effectively demonstrates a viable path for overcoming the sector’s primary barriers.

By selecting a platform that is both technologically advanced and compliant with Europe's formidable regulatory framework—including the IVDR and GDPR—Unilabs is not only future-proofing its own operations but also demonstrating how to securely manage cross-border health data at scale. This initiative will be watched closely by healthcare providers and policymakers as a real-world test of how to successfully digitize a core medical discipline across a continent.